How Long Is Radiation Treatment for Prostate Cancer?

Radiation treatment for prostate cancer ranges from a single day to about nine weeks, depending on the type of radiation, the dose schedule your oncologist selects, and whether hormone therapy is part of the plan. The most common approach today, external beam radiation with moderate hypofractionation, takes about four weeks. But some men finish in as few as five sessions spread over roughly a week and a half, while others on older conventional schedules spend eight to nine weeks coming in daily. Understanding which schedule applies to you starts with the kind of radiation being used and your cancer’s risk profile.

Conventional Fractionation and Why It Is Fading

For decades, the standard external beam course for prostate cancer involved 40 to 45 daily treatments delivered over more than eight to nine weeks.¹ Each session delivered a relatively small dose, around 1.8 to 2 Gy per fraction, building up to a total of roughly 74 to 78 Gy. This schedule was designed to exploit differences in how normal tissue and tumor cells repair radiation damage between sessions. The thinking was that many small doses would spare the bladder and rectum while still killing cancer cells.

That logic turned out to be partly wrong for prostate cancer specifically. Research showed that prostate tumors are unusually sensitive to large individual doses, meaning fewer, bigger fractions could work just as well or even better for tumor control without necessarily worsening side effects.² This finding set off a wave of clinical trials testing shorter courses, and those trials have largely succeeded. While some centers still use conventional fractionation, it has been overtaken by shorter schedules as the preferred approach.

Moderate Hypofractionation: The Four-Week Standard

Moderate hypofractionation delivers a higher dose per session across fewer visits, typically finishing in four to five weeks instead of eight or nine. The most widely validated schedule uses 60 Gy in 20 fractions over four weeks, and multiple large randomized trials have shown this to be just as effective as the longer conventional course in disease control and survival.³ One landmark trial directly compared 60 Gy in 20 fractions over four weeks against 78 Gy in 39 fractions over eight weeks and found no meaningful difference in outcomes.⁴

Other variations exist within this category. One European trial tested 56 Gy in 16 fractions over four weeks against 67 Gy in 25 fractions over five weeks, finding comparable toxicity at three years.⁵ The common thread is that four weeks has enough evidence behind it to be considered a new standard of care for all risk groups of localized prostate cancer.³ If you are starting external beam radiation today and your oncologist suggests a four-week course, that is firmly within the mainstream.

Ultrahypofractionation: Five Sessions or Fewer

At the other extreme from conventional fractionation, stereotactic body radiation therapy (SBRT) compresses the entire course into just five treatments, each delivering a large dose. A proton therapy study treating low- and intermediate-risk patients with five fractions found a median treatment time of nine days, with some patients finishing in as few as seven.⁶ Sessions are usually spaced every other day or a few days apart rather than daily, giving normal tissue extra recovery time between the large doses.

SBRT is most commonly offered for low-risk and favorable intermediate-risk prostate cancer. The appeal is obvious: instead of driving to a treatment center 20 or 40 times, you go roughly five times. Five-year outcomes from ultrahypofractionated courses look promising, and the schedule is increasingly used with both photon-based machines and proton therapy systems. That said, the very large dose per session demands extreme precision, and not every patient or anatomy is a good fit for it.

Brachytherapy: One Day or a Few Sessions

Brachytherapy places the radiation source inside or next to the prostate rather than aiming it from outside the body. There are two types, and their timelines differ sharply.

Low-dose-rate (LDR) brachytherapy involves implanting tiny radioactive seeds directly into the prostate during a single outpatient procedure, usually under anesthesia. You go home the same day. The seeds emit radiation continuously over weeks to months as they decay. From the patient’s perspective, treatment day itself is a one-time event, though recovery from the implant procedure takes a bit longer and follow-up imaging checks how the seeds are positioned.⁷

High-dose-rate (HDR) brachytherapy works differently. A radioactive source is temporarily placed inside catheters threaded into the prostate, delivers a concentrated dose over several minutes, and is then removed. When used as the sole treatment for low- to intermediate-risk disease, HDR monotherapy typically involves two or three sessions, with schedules such as 27 Gy in two fractions or about 34 Gy in three fractions. Disease-free survival rates above 90% for intermediate-risk patients have been reported when HDR is combined with a shorter course of external beam radiation.⁸ In that combination setting, the external beam component usually runs for four to five weeks at a reduced dose, with the HDR boost delivered before or after.

How Risk Level Shapes the Timeline

Prostate cancer is classified into risk groups based on factors like tumor grade, PSA level, and clinical stage. Those groupings have a real effect on how long your total treatment takes, both in terms of the radiation schedule itself and whether hormone therapy gets added to the mix.

For low-risk disease, many patients are candidates for the shortest approaches: SBRT in five sessions, LDR brachytherapy in one day, or moderate hypofractionation over four weeks without any additional therapy. Intermediate-risk disease, particularly when classified as “unfavorable intermediate” based on features like a higher-grade biopsy pattern or many positive cores, often warrants a longer or more intensive approach.⁹ These patients may still receive a four-week external beam course, but hormone therapy lasting four to six months is commonly added.

High-risk and locally advanced prostate cancer usually involves the most comprehensive treatment. The radiation itself may still follow a four-week hypofractionated schedule, but it is combined with androgen deprivation therapy (ADT) that extends the overall treatment timeline well beyond the radiation course itself.

Hormone Therapy and the Full Treatment Timeline

If your cancer is intermediate- or high-risk, the radiation portion is only part of the story. ADT, which suppresses testosterone to slow cancer growth, often begins months before radiation starts and continues for months or years afterward. This stretches the total active treatment timeline far beyond whatever the radiation schedule is.

A meta-analysis found that longer hormone treatment significantly reduced recurrences at all levels, including local recurrence and distant spread, compared to shorter courses.¹⁰ For high-risk patients, the optimal duration remains a matter of some debate. One analysis of a large cooperative group trial found that men with locally advanced disease who received more than five years of ADT had better outcomes than those treated for shorter periods.¹¹ In practice, high-risk patients often receive 18 months to three years of ADT, sometimes longer. A systematic review noted that trial protocols varied widely, with some arms lasting less than 12 months and others well beyond.¹²

So while the radiation itself may wrap up in four weeks, a high-risk patient’s treatment arc, including ADT, can span two to three years from start to finish. When patients ask how long treatment takes, clarifying whether they mean “how many weeks of radiation” or “how long until I’m done with everything” leads to very different answers.

The Planning Phase Before Radiation Begins

Before the first actual treatment session, you will go through a simulation and planning process that typically adds one to three weeks to your timeline. During simulation, imaging scans map your prostate and surrounding organs so the radiation team can design beam angles that target the tumor while avoiding as much healthy tissue as possible. One study of an MRI-based simulation workflow reported an imaging session lasting about 25 minutes, though the full planning process, including contouring the target and optimizing the treatment plan, extends over several days before you are cleared to begin.¹³

Some centers also place small markers called fiducial seeds or a hydrogel spacer between the prostate and rectum during this phase. These procedures are minor but add another appointment a week or two before radiation starts. If you are counting from “first appointment related to radiation” to “last treatment session,” plan on roughly two extra weeks at the front end regardless of which fractionation schedule follows.

What a Daily Session Actually Feels Like

Each external beam treatment session is quick. On a standard linear accelerator, you typically spend about 15 to 20 minutes in the treatment room, most of which is setup time: getting positioned on the table, aligning the machine with your internal anatomy using imaging, and then the actual radiation delivery, which takes only a few minutes. There is no pain during the beam itself.

Newer MR-guided machines that adapt the treatment plan in real time take considerably longer per session. One study comparing adaptive and non-adaptive workflows on an MR-Linac system found that adaptive sessions had a median duration of about 71 minutes, versus 36 minutes for non-adaptive treatments.¹⁴ Adaptive treatment is still relatively uncommon and tends to be offered at larger academic centers, but it is worth knowing that “a few minutes of radiation” can mean an hour-plus of table time if your plan uses this technology.

Missed Days and Treatment Interruptions

Life happens during weeks of daily treatment. Machine maintenance, holidays, illness, and scheduling conflicts all cause missed sessions. The good news is that for standard-length courses, a small number of gaps does not appear to meaningfully change cancer outcomes. One retrospective study looked at prostate cancer patients whose conventional courses were interrupted and found no significant differences in disease control, distant metastasis, cancer-specific survival, or overall survival when comparing men with more versus fewer missed days.¹⁵

That said, the picture changes when prolonged interruptions accumulate. A separate analysis of high-risk patients found that missing more than three days of external beam treatment was associated with worse overall survival, with a five-year rate of about 80% versus 83% for those who kept interruptions to three days or fewer.¹⁶ The same study found that a long delay between starting hormone therapy and beginning radiation was itself a risk factor. The practical takeaway: a day or two of missed treatment is not a crisis, but consistent attendance matters, especially for higher-risk disease. Missed sessions are typically tacked onto the end of the course, extending the total calendar time by however many days were skipped.

The Practical Burden of Longer Courses

One reason the shift toward shorter schedules matters so much has nothing to do with tumor biology and everything to do with the grind of daily treatment. A German cost analysis calculated that a conventional course required patients to travel roughly 1,600 km total to and from the treatment center, compared with about 850 km for moderate hypofractionation and around 240 km for ultrahypofractionation. The travel costs for the longest course were about seven times higher than for the shortest, and the carbon footprint shrank by up to 85% with fewer sessions.¹⁷

Beyond cost, longer courses are harder for some patients to complete. An analysis of U.S. treatment patterns found that Black patients were consistently less likely to receive hypofractionated radiation for prostate cancer, despite evidence that shorter regimens reduce the rate of treatment noncompletion and produce similar cancer outcomes.¹⁸ Barriers like transportation, time off work, caregiving responsibilities, and distance from a treatment center all compound over eight or nine weeks in ways that they simply do not over four weeks or five sessions. For many patients, a shorter course is not just equally effective; it is more likely to actually get finished.

Side Effects Across Different Schedules

A reasonable concern about delivering bigger doses per session is that it might cause worse side effects. Early clinical data suggested this could be an issue: one trial found that the short-course arm had higher rates of acute urinary toxicity (about 9%) compared with the longer conventional arm (about 5%), and acute rectal toxicity was also modestly higher in the short arm.¹⁹ However, late toxicity rates, the side effects that persist months or years afterward, were similar between the two arms in that same trial, and the hypofractionated dose used was lower than current standards.

More recent and larger trials of modern hypofractionated schedules have generally been reassuring. The four-week, 20-fraction course that is now considered standard was specifically designed to be “isoeffective,” meaning it aims to produce the same degree of both tumor kill and normal tissue effects as the longer course.³ For ultrahypofractionation with SBRT, the side-effect profile is still being characterized as long-term data matures, but early results have been encouraging. The main acute symptoms across all external beam schedules are similar: increased urinary frequency and urgency, mild rectal irritation, and fatigue. These peak toward the end of treatment and gradually improve over weeks to months.

When Proton Therapy Changes the Calendar

Proton beam therapy uses charged particles instead of X-rays, which allows it to deposit most of its energy at a specific depth and spare tissue beyond the target. In terms of scheduling, proton therapy follows the same range of fractionation options as photon-based radiation. Conventionally fractionated proton courses run about eight weeks. Hypofractionated proton schedules mirror their photon counterparts at four to five weeks. And as the ultrahypofractionated proton study mentioned earlier demonstrates, five-fraction proton SBRT can be completed in a median of nine days.⁶

Proton therapy is available at fewer centers and typically costs more, so access is a practical constraint. Whether protons offer a meaningful clinical advantage over modern photon techniques for prostate cancer is still debated; the scheduling timelines themselves are not a differentiator. If your oncologist recommends proton therapy, expect a similar number of sessions and weeks as you would with a comparable photon-based plan.

A Quick Reference for Treatment Timelines

Because the range is wide and the terminology can blur together, here is a snapshot of the main radiation approaches and their typical durations:

Conventional EBRT: 39–45 sessions over about 8–9 weeks
Moderate hypofractionation: 16–20 sessions over 4–5 weeks
Ultrahypofractionation (SBRT): 5 sessions over roughly 1–2 weeks
LDR brachytherapy: 1 implant procedure (seeds emit radiation over weeks internally)
HDR brachytherapy alone: 2–3 sessions over 1–2 weeks
HDR boost with EBRT: 1–2 HDR sessions plus 4–5 weeks of external beam

Add one to three weeks of planning and simulation at the front end, and potentially months to years of hormone therapy for intermediate- and high-risk disease. The radiation itself is only one layer in what can be a longer treatment arc, but knowing the duration of that layer helps you plan your work schedule, arrange transportation, and set realistic expectations for the weeks ahead.

1
PubMed Central. Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer
2
PubMed. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue
3
Cancer/Radiothérapie. Moderate hypofractionated radiotherapy for localised prostate cancer: A new standard of care
4
PubMed. Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer
5
PubMed. Moderate hypofractionated radiotherapy for prostate cancer: 3-year toxicity results of a multicentre randomized phase 3, non-inferiority trial
6
International Journal of Radiation Oncology*Biology*Physics. Ultrahypofractionated Proton Radiation Therapy in the Treatment of Low and Intermediate-Risk Prostate Cancer-5-Year Outcomes
7
PubMed. Potential impact of prostate edema on the dosimetry of permanent seed implants using the new 131Cs (model CS-1) seeds
8
PubMed Central. High dose-rate brachytherapy in the treatment of prostate cancer
9
European Urology. A New Risk Classification System for Therapeutic Decision Making with Intermediate-risk Prostate Cancer Patients Undergoing Dose-escalated External-beam Radiation Therapy
10
PubMed Central. Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: meta-analysis of randomized trials
11
PubMed Central. Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31
12
PubMed Central. Optimal duration of androgen deprivation therapy following radiation therapy in intermediate- or high-risk non-metastatic prostate cancer: A systematic review and meta-analysis
13
PubMed Central. Clinical workflow for MR-only simulation and planning in prostate
14
PubMed Central. Long-term patient experience with online MR-guided radiotherapy: adaptive versus non-adaptive workflow
15
PubMed Central. Effects of Interruptions of External Beam Radiation Therapy on Outcomes in Patients with Prostate Cancer
16
Clinical and Translational Radiation Oncology. Optimal timing of radiotherapy in high risk prostate cancer: Do missed days matter?
17
PubMed. Travel costs and ecologic imprint associated with different fractionation schedules in prostate cancer radiotherapy
18
PubMed Central. Shorter Radiation Regimens and Treatment Noncompletion Among Patients With Breast and Prostate Cancer in the United States: An Analysis of Racial Disparities in Access and Quality
19
International Journal of Radiation Oncology, Biology, Physics. Randomized Trial of a Hypofractionated Radiation Schedule Versus a Conventional Fractionation Schedule for Localized Prostate Cancer